A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Felzartamab (Primary)
- Indications IgA nephropathy
- Focus Proof of concept; Therapeutic Use
- Acronyms IGNAZ
- Sponsors Human Immunology Biosciences; MorphoSys
- 13 Jun 2024 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
- 29 May 2024 Status changed from active, no longer recruiting to completed.
- 29 May 2024 This study has been completed in Belgium, according to European Clinical Trials Database record.